Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
19 12월 2023 - 9:30PM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced abstract acceptance and an upcoming rapid oral
presentation of updated interim monotherapy data from its Phase 1/2
clinical trial evaluating HPN328 in small cell lung cancer (SCLC)
and other neuroendocrine tumor types at the American Society of
Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) being
held in San Francisco, CA and virtually on January 25-27, 2024.
HPN328 targets delta-like ligand 3 (DLL3) and is derived from
Harpoon’s proprietary Tri-specific T cell Activating Construct
(TriTAC®) platform designed to recruit a patient’s own immune cells
to kill tumor cells.
Details of the ASCO-GU presentation are as
follows:
Title: “Interim Results from a Phase 1/2 Study
of HPN328, a Tri-Specific, Half-Life (T1/2) Extended DLL3-targeting
T-Cell Engager in Patients with Neuroendocrine Prostate Cancer
(NEPC) and other Neuroendocrine Neoplasms (NEN)”
Abstract number: 121
Session: Rapid Oral Abstract Session A:
Prostate Cancer
Session track: Prostate Cancer - Advanced |
Prostate Cancer - Localized
Session date & time: Thursday, January 25,
2024 at 4:15 PM – 5:00 PM PST
Presenter: Himisha Beltran, M.D. | Dana-Farber
Cancer Institute
Location: Level 3, Ballroom | Livestream
The presentation will also be available on Harpoon’s website
under Publications following the session.
For more details about the ASCO-GU Annual Meeting, please visit:
https://conferences.asco.org/gu/attend
About HPN328HPN328 targets delta-like canonical
Notch ligand 3 (DLL3) and is based on Harpoon’s proprietary
Tri-specific T cell Activating Construct (TriTAC®) platform
designed to recruit a patient’s own immune cells to kill tumor
cells. HPN328 is being evaluated as monotherapy in an ongoing
open-label, multicenter, two-part study to assess the safety,
tolerability, and pharmacokinetics in patients with advanced
cancers associated with the expression of DLL3.
In March 2022, the U.S. Food and Drug Administration (FDA)
granted Orphan Drug Designation to HPN328 for the treatment of
SCLC.
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers designed to harness the
power of the body’s immune system to treat patients suffering from
cancer and other diseases. T cell engagers are engineered proteins
that direct a patient’s own T cells to kill target cells that
express specific proteins, or antigens, carried by the target
cells. Using its proprietary Tri-specific T cell Activating
Construct (TriTAC®) platform, Harpoon is developing a pipeline of
novel TriTACs initially focused on the treatment of solid
tumors and hematologic malignancies. Harpoon has also developed a
proprietary ProTriTAC™ platform, which applies a prodrug
concept to its TriTAC platform to create a therapeutic T cell
engager that remains inactive until it reaches the tumor. Harpoon’s
third proprietary technology platform, extended release TriTAC-XR,
is designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“continue,” “demonstrate,” “further,” “remain,” “potential,”
“will,” and similar expressions (as well as other words or
expressions referencing future events, conditions, or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
These forward-looking statements involve risks and uncertainties
that could cause Harpoon Therapeutics’ clinical development
programs, future results, or performance to differ significantly
from those expressed or implied by the forward-looking statements.
Forward-looking statements in this press release include but are
not limited to, statements about the expected progress, results,
and plans pertaining to Harpoon Therapeutics’ clinical trials,
including timing, scope, design, enrollment plans and interim
results of clinical trials and the safety and tolerability profile
of product candidates, the association of interim clinical data and
preclinical results with potential treatment outcomes, achievement
of future milestones and other statements that are not historical
fact. These and other factors that may cause Harpoon Therapeutics’
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Harpoon Therapeutics’ filings with the U.S. Securities and
Exchange Commission. Except as required by law, Harpoon
Therapeutics assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contact:Ana KaporHarpoon
Therapeuticsinvestors@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024